KLRG1 and neoplasm: In corroboration with our findings, blockades of CD38 and KLRG1 are being developed as therapeutic strategies to promote tumor immunity and to ameliorate resistance to PD-1/PD-L1 checkpoint inhibitors and other cancer therapies (40, 41, 43, 48, 93).